Higher plasma bilirubin predicts veno-occlusive disease in early childhood undergoing hematopoietic stem cell transplantation with cyclosporine

Table 2 Median trough plasma concentrations and doses of cyclosporine in hematopoietic stem cell transplantation patients

Contents		G#1 (n = 25)	G#2 (n = 70)	G#3 (n = 28)
iv	Trough plasma concentrationb (ng/mL)	535.6 (264.0-1214.0)a	448.9 (184.5-1070.0)	333.1 (152.5-819.0)
	Dose (mg/kg)	5.8 (3.9-7.7)	6.1 (3.5-14.2)	6.0 (3.8-9.3)
PO	Trough plasma concentrationb (ng/mL)	345.9 (166.0-686.5)	247.7 (40.0-496.5)	204.4 (33.0-302.5)
	Dose (mg/kg)c	8.2 (3.4-11.4)	8.2 (1.6-17.5)	10.6 (6.0-24.6)

^aThe values in parenthesis represent the minimum and maximum trough plasma concentrations of cyclosporine;

^bG#1 was significantly different from G#2 or G#3 using Duncan test;

^cG#3 was significantly different from G#1 or G#2 using Duncan test. iv: Intravenous administration; PO: Per Os, which means oral administration.